AAPL 258.8189 0.2397% MSFT 439.14 -0.0432% NVDA 140.185 -0.025% GOOGL 196.0128 -0.0496% GOOG 197.54 -0.0152% AMZN 227.87 -0.5152% META 603.74 -0.6598% AVGO 245.6915 2.5081% TSLA 452.9125 -2.0264% TSM 204.19 -1.0372% LLY 797.2122 0.1938% V 320.96 0.0967% JPM 242.37 0.0248% UNH 509.62 0.6955% NVO 87.85 0.5494% WMT 92.38 -0.3237% LVMUY 132.91 0.4459% XOM 106.31 -0.0846% LVMHF 664.0 0.9119% MA 536.2159 0.0944%
Last update at 2024-12-26T18:51:00Z
Inovio (INO) Surges 6.8%: Is This an Indication of Further Gains?
Wed 09 Oct 24, 09:38 AMInsmed Inc. (INSM): Hedge Funds Are Bullish On This NASDAQ Stock Right Now
Sun 06 Oct 24, 01:23 PMIs Insmed Incorporated (INSM) the Best Performing Long Term Stock in 2024?
Sun 29 Sep 24, 10:38 AMIs Insmed Inc. (INSM) the Best Performing Stock in 2024?
Thu 26 Sep 24, 04:25 AMInsmed Inc. (INSM): A Top Mid-Cap Biopharma Stock with Compelling Growth Potential
Sat 21 Sep 24, 02:14 PMInsmed Incorporated (INSM): Hedge Funds Are Recommending This Biotech Stock Now
Sun 08 Sep 24, 05:52 AMInsmed (INSM) Rose Due to Positive Trial Results
Thu 29 Aug 24, 07:30 AMInsmed Stock Surges 168% in the Past Six Months: Here's Why
Tue 27 Aug 24, 03:07 PM| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Income before tax | -480.15100M | -436.41200M | -292.68800M | -253.56000M | -324.07600M |
| Minority interest | - | - | - | - | - |
| Net income | -481.53400M | -434.65400M | -294.09000M | -254.33700M | -324.27700M |
| Selling general administrative | 244.98M | 234.27M | 203.61M | 210.80M | 168.22M |
| Selling and marketing expenses | 20.80M | - | - | - | - |
| Gross profit | 190.23M | 144.31M | 124.54M | 112.25M | 7.41M |
| Reconciled depreciation | 10.33M | 14.18M | 14.15M | 10.18M | 4.83M |
| Ebit | -478.12300M | -367.76000M | -265.23200M | -235.24500M | -306.73600M |
| Ebitda | -458.20700M | -373.37200M | -259.82400M | -230.78300M | -305.48700M |
| Depreciation and amortization | 19.92M | -5.61200M | 5.41M | 4.46M | 1.25M |
| Non operating income net other | 3.62M | -20.84500M | 2.11M | 9.39M | 8.73M |
| Operating income | -478.12300M | -367.76000M | -265.23200M | -235.24500M | -307.33800M |
| Other operating expenses | 723.48M | 556.22M | 429.64M | 371.71M | 317.17M |
| Interest expense | 26.45M | 40.47M | 29.56M | 27.70M | 25.47M |
| Tax provision | 1.38M | -1.75800M | 1.40M | 0.78M | 0.20M |
| Interest income | - | - | - | 17.78M | 15.13M |
| Net interest income | -26.44600M | -40.47300M | -29.56400M | -27.70500M | -25.47200M |
| Extraordinary items | - | - | - | - | - |
| Non recurring | - | - | - | - | - |
| Other items | - | - | - | - | - |
| Income tax expense | 1.38M | -1.75800M | 1.40M | 0.78M | 0.20M |
| Total revenue | 245.36M | 188.46M | 164.41M | 136.47M | 9.84M |
| Total operating expenses | 668.36M | 512.07M | 389.77M | 347.50M | 314.75M |
| Cost of revenue | 55.13M | 44.15M | 39.87M | 24.21M | 2.42M |
| Total other income expense net | -2.02800M | -68.65200M | -27.45600M | -18.31500M | 8.73M |
| Discontinued operations | - | - | - | - | - |
| Net income from continuing ops | -481.53400M | -434.65400M | -294.09000M | -254.33700M | -324.27700M |
| Net income applicable to common shares | -481.53400M | -434.65400M | -294.09000M | -254.33700M | -324.27700M |
| Preferred stock and other adjustments | - | - | - | - | - |
| Breakdown | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 |
| Total assets | 1329.84M | 1656.43M | 1243.51M | 796.15M | 742.30M |
| Intangible assets | 63.70M | 68.76M | 73.81M | 49.26M | 53.68M |
| Earning assets | - | - | - | - | - |
| Other current assets | 24.18M | 25.47M | 28.90M | 23.98M | 20.22M |
| Total liab | 1661.76M | 1568.48M | 833.04M | 520.27M | 480.62M |
| Total stockholder equity | -331.92300M | 87.95M | 410.47M | 275.88M | 261.67M |
| Deferred long term liab | - | 37.59M | 72.04M | 47.29M | 52.14M |
| Other current liab | 214.99M | 131.66M | 89.25M | 63.40M | 0.28M |
| Common stock | 1.48M | 1.36M | 1.19M | 1.03M | 0.90M |
| Capital stock | 1.48M | 1.36M | 1.19M | 1.03M | 0.90M |
| Retained earnings | -3446.14500M | -2696.57800M | -2265.24300M | -1830.58900M | -1536.49900M |
| Other liab | - | 60.49M | 95.74M | 9.18M | 10.61M |
| Good will | 136.11M | 136.11M | 136.11M | 49.26M | 53.68M |
| Other assets | - | 113.69M | 50.99M | 70.05M | 72.45M |
| Cash | 482.37M | 1074.04M | 716.78M | 532.76M | 487.43M |
| Cash and equivalents | - | - | - | - | - |
| Total current liabilities | 225.63M | 190.24M | 135.17M | 118.81M | 85.24M |
| Current deferred revenue | -65.39300M | - | - | - | 59.52M |
| Net debt | 721.62M | 103.83M | -104.51400M | -127.91400M | -90.39100M |
| Short term debt | 10.64M | 8.13M | 10.14M | 12.56M | 12.26M |
| Short long term debt | - | - | - | - | - |
| Short long term debt total | 1203.99M | 1177.87M | 612.27M | 404.84M | 397.04M |
| Other stockholder equity | 3113.49M | 2782.42M | 2673.56M | 2105.25M | 1797.29M |
| Property plant equipment | - | 56.49M | 52.95M | 53.95M | 60.18M |
| Total current assets | 929.06M | 1273.38M | 837.04M | 622.89M | 555.19M |
| Long term investments | - | 0.00000M | 50.04M | - | - |
| Net tangible assets | - | -116.91500M | 200.55M | 226.62M | 207.99M |
| Short term investments | 298.07M | 74.24M | - | - | - |
| Net receivables | 41.19M | 29.71M | 24.35M | 16.56M | 19.23M |
| Long term debt | 1155.31M | 1125.25M | 566.59M | 356.32M | 335.94M |
| Inventory | 83.25M | 69.92M | 67.01M | 49.59M | 28.31M |
| Accounts payable | 65.39M | 50.46M | 35.78M | 42.85M | 13.18M |
| Total permanent equity | - | - | - | - | - |
| Noncontrolling interest in consolidated entity | - | - | - | - | - |
| Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
| Accumulated other comprehensive income | -0.74500M | 0.76M | 0.97M | 0.19M | -0.01000M |
| Additional paid in capital | - | - | - | - | - |
| Common stock total equity | - | 1.36M | 1.19M | 1.03M | 0.90M |
| Preferred stock total equity | - | - | - | - | - |
| Retained earnings total equity | - | -2696.57800M | -2265.24300M | -1830.58900M | -1536.49900M |
| Treasury stock | - | - | - | - | - |
| Accumulated amortization | - | - | - | - | - |
| Non currrent assets other | 96.57M | 76.10M | 50.99M | 26.77M | 20.31M |
| Deferred long term asset charges | - | - | - | - | - |
| Non current assets total | 400.77M | 383.05M | 406.47M | 173.26M | 187.10M |
| Capital lease obligations | 48.68M | 52.62M | 45.68M | 48.52M | 61.10M |
| Long term debt total | - | 1125.25M | 566.59M | 356.32M | 335.94M |
| Breakdown | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|
| Type | yearly | yearly | yearly | yearly | yearly |
| Date | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Investments | -34.58400M | -50.29200M | -6.82200M | -42.26800M | -14.81400M |
| Change to liabilities | 50.01M | -7.57500M | 24.93M | -3.24500M | 33.80M |
| Total cashflows from investing activities | -34.58400M | -64.28500M | -6.82200M | -42.26800M | -14.81400M |
| Net borrowings | 332.22M | 321.70M | -0.93600M | -0.93600M | 377.93M |
| Total cash from financing activities | 793.27M | 612.55M | 271.00M | 285.28M | 386.74M |
| Change to operating activities | -35.29900M | -25.43100M | -14.26900M | -23.00500M | 24.41M |
| Net income | -481.53400M | -434.65400M | -294.09000M | -254.33700M | -324.27700M |
| Change in cash | 357.25M | 184.03M | 45.33M | -7.64300M | 113.91M |
| Begin period cash flow | 716.78M | 532.76M | 487.43M | 495.07M | 381.17M |
| End period cash flow | 1074.04M | 716.78M | 532.76M | 487.43M | 495.07M |
| Total cash from operating activities | -400.43900M | -363.30200M | -219.34800M | -250.64900M | -257.97700M |
| Issuance of capital stock | 292.15M | 269.89M | 245.87M | 261.07M | 0.00000M |
| Depreciation | 10.33M | 14.18M | 14.15M | 10.18M | 4.83M |
| Other cashflows from investing activities | - | -6.70400M | -0.58200M | - | -1.72400M |
| Dividends paid | - | - | - | - | - |
| Change to inventory | -1.71400M | -17.45600M | -21.18000M | -21.28100M | -7.03200M |
| Change to account receivables | -6.42300M | -8.11800M | 2.67M | -13.71700M | -5.51500M |
| Sale purchase of stock | 311.66M | 291.92M | 271.94M | 280.77M | 8.81M |
| Other cashflows from financing activities | 501.12M | 567.66M | 26.07M | 24.20M | 444.58M |
| Change to netincome | 46.26M | 71.04M | 36.16M | 26.97M | 28.45M |
| Capital expenditures | 9.88M | 7.29M | 6.82M | 42.27M | 14.81M |
| Change receivables | -6.42300M | -8.11800M | 2.67M | -13.71700M | -5.51500M |
| Cash flows other operating | -21.36300M | 19.27M | 16.62M | 3.38M | -5.51400M |
| Exchange rate changes | - | - | 0.49M | -0.00400M | -0.04500M |
| Cash and cash equivalents changes | 358.25M | 184.96M | 45.33M | -7.64300M | 113.91M |
| Change in working capital | 6.58M | -58.58000M | -2.95400M | -62.96900M | 15.74M |
| Stock based compensation | 57.69M | 46.02M | 36.16M | 26.97M | 26.24M |
| Other non cash items | 6.50M | 52.04M | 27.39M | 29.50M | 17.29M |
| Free cash flow | -410.31700M | -370.59100M | -226.17000M | -292.91700M | -272.79100M |
Sector: Healthcare Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
|---|---|---|---|---|---|---|---|---|
| INSM Insmed Inc |
0.66 0.94% | 71.19 | - | - | 13.26 | 25.45 | 14.66 | -6.7757 |
| NVO Novo Nordisk A/S |
0.48 0.55% | 87.85 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
| NONOF Novo Nordisk A/S |
0.75 0.86% | 87.75 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
| VRTX Vertex Pharmaceuticals Inc |
1.19 0.29% | 409.37 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
| REGN Regeneron Pharmaceuticals Inc |
0.27 0.04% | 714.74 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, New Jersey.
700 US Highway 202/206, Bridgewater, NJ, United States, 08807
| Name | Title | Year Born |
|---|---|---|
| Mr. William H. Lewis J.D., M.B.A. | Pres, CEO & Chairman | 1969 |
| Ms. Sara M. Bonstein MBA | Chief Financial Officer | 1981 |
| Mr. Roger Adsett | Chief Operating Officer | 1969 |
| Ms. S. Nicole Schaeffer | Chief People Strategy Officer | 1968 |
| Dr. Martina Flammer M.B.A., M.D. | Chief Medical Officer | 1964 |
| Mr. John Goll III | Sr. VP & Chief Accounting Officer | NA |
| Eleanor Barisser | Associate Director of Investor Relations | NA |
| Mr. Michael Alexander Smith | Sr. VP & Gen. Counsel | 1978 |
| Mandy Fahey | Exec. Director of Corp. Communications | NA |
| Mr. John Drayton Wise | Sr. VP, Head of United States & Chief Commercial Officer | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
US 
AU
UK
CA
NZ
Please wait processing your request...